As soon as they release a PR now that their IPO quiet period is over, we should see some interest return this over IPO pricing.
The Aegis Capital Corp. analyst, Raghuram Selvaraju, Ph.D, who offered an 18 month price target of $60 which caused the spike into the low $12s, is HIGHLY regarded in the bio-tech sector.
http://www.thelifesciencesreport.com/pub/htdocs/expert.html?id=7096
Recent EVOK News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 11:01:20 AM
- Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI • GlobeNewswire Inc. • 06/17/2024 12:30:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:00:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 10:09:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 09:02:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:56:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:53:59 PM
- Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference • GlobeNewswire Inc. • 05/16/2024 08:02:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:20:33 PM
- Evoke Pharma Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/14/2024 08:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:18 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 05/14/2024 08:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:00:15 PM
- Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications • GlobeNewswire Inc. • 04/17/2024 12:30:27 PM
- Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer • GlobeNewswire Inc. • 03/21/2024 08:15:59 PM
- Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:05:28 PM
- Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024 • GlobeNewswire Inc. • 03/07/2024 09:10:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:15:06 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 09:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:00:04 PM
- Evoke Pharma Announces Closing of $7.5 Million Public Offering • GlobeNewswire Inc. • 02/14/2024 12:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:15:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/09/2024 10:14:30 PM
- Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million • GlobeNewswire Inc. • 02/09/2024 12:30:48 PM
FEATURED ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM